Canopy Growth Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Luc Mongeau
- Full Time Employees
- 1,128
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1 Hershey Drive Smiths Falls ON Canada K7A 0A8
- IPO Date
- Apr 7, 2014
- CIK
- 0001737927
- Website
- canopygrowth.com
- Similar Companies
- Business
- Canopy Growth Corporation is a leading global diversified cannabis company engaged in the cultivation, production, and sale of cannabis and cannabinoid-based products. The company offers an extensive portfolio including dried cannabis flower, pre-rolls, oils, softgels, edibles, and beverages, catering to both medical and recreational markets. Its core brands include Tweed, 7ACRES, DOJA, Deep Space, Claybourne, and medical cannabis through its subsidiary Storz & Bickel GmbH & Co. KG, which specializes in cannabis vaporization devices. Canopy operates large-scale GMP-certified indoor and greenhouse cultivation facilities primarily in Canada, with significant operations in the United States, Germany, the United Kingdom, and emerging markets in Australia, Denmark, Peru, and Brazil. Founded in 2013 and headquartered in Smiths Falls, Ontario, Canada, the company focuses on rigorous quality assurance, genetic research, and innovative product development. In the past two years, Canopy Growth has strategically sharpened its operational focus by divesting non-cannabis businesses and adopting an asset-light, brand-driven model to reduce complexity and cost structure. The company has advanced its product innovation with launches such as the advanced all-in-one vape devices featuring CCELL technology under the Tweed and 7ACRES brands to capture demand in premium vaporization formats. Financially, Canopy has improved stability by reducing costs, cash burn, and debt, while targeting positive adjusted EBITDA. It has made significant operational shifts including reallocating its Kelowna DOJA operations towards specialized medical cannabis cultivation and expanding into the wellness market with hemp-derived products under initiatives like Wana Wellness. Canopy also maintains a strategic option to acquire Acreage Holdings in the US, pending federal legalization, positioning it for accelerated entry into the American cannabis market. Canopy Growth's comprehensive range of cannabis products, global geographic footprint, and recent emphasis on operational efficiency and innovation underpin its role as a market leader in the cannabis industry. The company continues to focus on premium and mainstream cannabis products designed to improve lives while pursuing growth through strategic partnerships, focused market expansion, and advanced product offerings. It employs approximately 960 people and reported revenue growth and margin improvements in its Canadian cannabis segment amid ongoing cost reduction efforts. Its headquarters remain at 1 Hershey Drive, Smiths Falls, Ontario.
Company News
Should You Buy Canopy Growth Stock on the Rebound?
Better Cannabis Stock to Buy Right Now: Canopy Growth or Tilray Brands?
3 Top Marijuana Stocks to Watch in September 2026
Cannabis Operator CGC Rises 15% in a Month: Time to Buy, Hold or Sell?
Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%: Here's Why TLRY Is Still Down 47% YTD
Top Canadian Cannabis Stocks to Watch in August 2026
Canopy Growth Announces Mailing of Proxy Materials for 2026 Annual General and Special Meeting – Urges Shareholders to Vote Now
Curaleaf Wants to Buy Aurora Cannabis for $272 Million. Is Canopy Growth the Next Marijuana Takeover Target?
Marijuana reform is emerging as a midterm elections issue on both sides of the aisle
Canopy Growth Secures Renewed EU GMP Certification at Kincardine as European Medical Cannabis Business Grows
Will Canopy Growth Get Acquired?
Canopy Growth Targets European Cannabis Expansion After MTL Deal and Cost Cuts
Canopy Growth: Penny Stock Purgatory -- or Cannabis Rebound in the Making?
Why Rescheduling Might Not Move Canopy Growth's Stock as Much as You Think
Canopy Growth Q1 Earnings Call Highlights
Canopy Growth reports fiscal first quarter revenue growth, improved margins
Canopy Growth Sees Steady Progress on Profitability Measures
Canopy Growth Corporation (CGC) Reports Q1 Loss, Tops Revenue Estimates
Canopy Growth Reports First Quarter Fiscal Year 2027 Financial Results; Delivers 13% Net Revenue Growth with Contributions from All Businesses
Canopy Growth Reports First Quarter Fiscal Year 2027 Financial Results; Delivers 13% Net Revenue Growth with Contributions from All Businesses